International Journal of Clinical Case Reports, 2025, Vol.15, No.3, 139-147 http://medscipublisher.com/index.php/ijccr 145 One way is to use two drugs that work differently. For example, using a PARP inhibitor with an immune drug. One stops the cancer from fixing its DNA. The other helps the immune system fight back (Roszik et al., 2018). Another choice is to begin with one kind of treatment and add another one afterward. This is known as maintenance therapy (Ang and Chan, 2024). Some drugs also change the area around the tumor. They improve blood flow or make it easier for immune cells to get in. This could also make other treatments work more effectively (Odiase et al., 2021). In the future, these new drugs and smart combos could help more people live longer and feel better. Fighting resistance is a big part of what comes next. 7 Concluding Remarks Using targeted drugs with chemo has changed the way doctors treat cervical cancer. This is most helpful when the cancer is in a late stage or comes back after earlier treatment. Large studies like GOG-240 and KEYNOTE-158 show that this mix helps patients live longer. It also makes the cancer grow more slowly. Bevacizumab works by stopping new blood vessels from feeding the tumor. Pembrolizumab helps the immune system spot the cancer and fight it. These two drugs work even better when used with chemo. They slow down the cancer and help patients live more months. But there are also some downsides. These treatments can cause strong side effects. Some people get high blood pressure, stomach problems, or issues with their immune system. These problems can make it hard for people to keep taking the drugs. Another issue is that cancer can learn to fight back. It may start growing blood vessels in other ways or hide from the immune system. So, while the treatment works at first, it might stop working over time. Even with these problems, the results from the studies are hopeful. Using both types of drugs gives doctors more ways to treat each patient in a way that fits them best. This kind of treatment is a big step forward. It helps treat the cancer and also stops it from hiding from the immune system. Doctors can use tests—like checking for PD-L1-to find which patients are most likely to benefit. Still, there are challenges. These drugs are very expensive. In many poorer countries, people can’t afford them. Hospitals there may also not have the tools or trained staff to use these treatments safely. To fix this, we need cheaper drug prices, better healthcare systems, and more clinical trials in those places. Doctors also need to watch patients closely. Catching side effects early and helping patients manage them can make a big difference. It helps them stay on treatment and feel better. In short, this kind of mixed treatment is very helpful. It not only gives patients more time to live but also makes them feel better. But there are still some challenges. The medicine can be expensive, and some people stop getting results. Side effects can also be hard to handle. We need more studies to deal with these problems. With fairer healthcare and easier access, more people around the world can benefit from this kind of treatment. Acknowledgments Thanks to Dr. Liu in this project team for collecting and combing the literature during the study. Conflict of Interest Disclosure The author affirms that this research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest. References Ang D., and Chan J., 2024, Evolving standards and future directions for systemic therapies in cervical cancer, Journal of Gynecologic Oncology, 35(2): e65. https://doi.org/10.3802/jgo.2024.35.e65 Arbyn M., Weiderpass E., Bruni L., De Sanjosé S., Saraiya M., Ferlay J., and Bray F., 2019, Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis, The Lancet. Global Health, 8(2): e191-e203. https://doi.org/10.1016/S2214-109X(19)30482-6 Bhattacharjee R., Dey T., Kumar L., Kar S., Sarkar R., Ghorai M., Malik S., Jha N.K., Vellingiri B., Kesari K.K., de la Lastra J.M.P., and Dey A., 2022, Cellular landscaping of cisplatin resistance in cervical cancer, Biomedicine and Pharmacotherapy, 153: 113345.
RkJQdWJsaXNoZXIy MjQ4ODYzNA==